Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose quadrivalent influenza vaccine in adults aged 60 years and older
NL-OMON48124Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of quadrivalent influenza vaccine in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Hemagglutination inhibition antibody titers at Day 28. Started Oct 2019; status: active, not recruiting.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON48124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48124.